-
公开(公告)号:US09308181B2
公开(公告)日:2016-04-12
申请号:US13791460
申请日:2013-03-08
申请人: Nuvo Research Inc.
发明人: Edward T. Kisak , John M. Newsam , Dominic King-Smith , Pankaj Karande , Samir Mitragotri , Tejas Desai , Wade A. Hull
IPC分类号: A61K31/196 , A61K31/405 , A61K9/70 , A61K31/192 , A61K31/40 , A61K31/407 , A61K31/5415 , A61K47/14 , A61K31/19 , A61K31/195 , A61K31/444 , A61K9/00 , A61K9/06 , A61F7/03 , A61K47/12 , A61K47/18 , A61K47/20 , A61K45/06 , A61K31/568 , A61K31/137 , A61K31/167 , A61K31/245 , A61F7/02
CPC分类号: A61K9/703 , A61F7/03 , A61F2007/0261 , A61K9/0014 , A61K9/06 , A61K9/7084 , A61K31/137 , A61K31/167 , A61K31/19 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/245 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/444 , A61K31/5415 , A61K31/568 , A61K45/06 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/20 , A61K2300/00
摘要: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
摘要翻译: 本公开内容涉及局部制剂,透皮系统和相关方法。 在一个实施方案中,提供了包括局部麻醉剂,第一化合物和第二化合物的局部制剂。 第一化合物和第二化合物不同,各自选自N-月桂酰肌氨酸,辛基硫酸钠,月桂酸甲酯,肉豆蔻酸异丙酯,油酸,油酸甘油酯和月桂基磺基乙酸钠。
-
公开(公告)号:US20130337031A1
公开(公告)日:2013-12-19
申请号:US13791460
申请日:2013-03-08
申请人: Nuvo Research Inc.
发明人: Edward T. Kisak , John M. Newsam , Dominic King-Smith , Pankaj Karande , Samir Mitragotri , Tejas Desai , Wade A. Hull
IPC分类号: A61K9/70 , A61K31/405 , A61K31/5415 , A61K31/40 , A61K31/407 , A61K31/196 , A61K31/192
CPC分类号: A61K9/703 , A61F7/03 , A61F2007/0261 , A61K9/0014 , A61K9/06 , A61K9/7084 , A61K31/137 , A61K31/167 , A61K31/19 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/245 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/444 , A61K31/5415 , A61K31/568 , A61K45/06 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/20 , A61K2300/00
摘要: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
摘要翻译: 本公开内容涉及局部制剂,透皮系统和相关方法。 在一个实施方案中,提供了包括局部麻醉剂,第一化合物和第二化合物的局部制剂。 第一化合物和第二化合物不同,各自选自N-月桂酰肌氨酸,辛基硫酸钠,月桂酸甲酯,肉豆蔻酸异丙酯,油酸,油酸甘油酯和月桂基磺基乙酸钠。
-
公开(公告)号:US20130079404A1
公开(公告)日:2013-03-28
申请号:US13680623
申请日:2012-11-19
申请人: Nuvo Research Inc.
CPC分类号: A61K47/20 , A61K9/2886 , A61K31/19 , A61K31/195 , A61K31/40 , A61K31/444 , A61K31/5415 , A61K47/12 , A61K47/14 , A61K47/16
摘要: It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.
摘要翻译: 已经发现,化合物的某些组合是优异的渗透增强剂,因此,可以掺入局部制剂以促进活性剂的给药。 渗透增加的增加也可能导致制剂中皮肤刺激物的总浓度降低。 本文描述了局部制剂,其包含(i)选自利多卡因和丁卡因中的至少一种的活性剂; (ii)第一化合物和(iii)第二化合物,其中第一化合物和第二化合物不同,并且各自选自N-月桂酰肌氨酸,辛基硫酸钠,月桂酸甲酯,肉豆蔻酸异丙酯,油酸 酸,油酸甘油酯和月桂基磺基乙酸钠。
-
公开(公告)号:US20150297723A1
公开(公告)日:2015-10-22
申请号:US14578812
申请日:2014-12-22
申请人: Nuvo Research Inc.
发明人: Edward T. Kisak , John M. Newsam , Dominic King-Smith , Pankaj Karande , Samir Mitragotri , Wade A. Hull , Ngoc Truc-Chi Vo
IPC分类号: A61K47/18 , A61K47/14 , A61K47/12 , A61K31/573
CPC分类号: A61K31/573 , A61F7/03 , A61F2007/0261 , A61K8/361 , A61K8/37 , A61K8/375 , A61K8/42 , A61K8/463 , A61K9/0014 , A61K9/06 , A61K31/135 , A61K31/192 , A61K31/196 , A61K31/568 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/183 , A61K47/20 , A61Q19/00 , A61K31/167 , A61K2300/00 , A61K31/245
摘要: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
摘要翻译: 本公开涉及局部制剂和相关方法。 在一个实施方案中,提供了包含至少一种皮质类固醇,第一化合物和第二化合物的局部制剂。 第一化合物和第二化合物不同,各自选自N-月桂酰肌氨酸,辛基硫酸钠,月桂酸甲酯,肉豆蔻酸异丙酯,油酸,油酸甘油酯和月桂基磺基乙酸钠。
-
公开(公告)号:US08513304B2
公开(公告)日:2013-08-20
申请号:US13680623
申请日:2012-11-19
申请人: Nuvo Research Inc.
CPC分类号: A61K47/20 , A61K9/2886 , A61K31/19 , A61K31/195 , A61K31/40 , A61K31/444 , A61K31/5415 , A61K47/12 , A61K47/14 , A61K47/16
摘要: It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.
摘要翻译: 已经发现,化合物的某些组合是优异的渗透增强剂,因此,可以掺入局部制剂以促进活性剂的给药。 渗透增加的增加也可能导致制剂中皮肤刺激物的总浓度降低。 本文描述了局部制剂,其包含(i)选自利多卡因和丁卡因中的至少一种的活性剂; (ii)第一化合物和(iii)第二化合物,其中第一化合物和第二化合物不同,并且各自选自N-月桂酰肌氨酸,辛基硫酸钠,月桂酸甲酯,肉豆蔻酸异丙酯,油酸 酸,油酸甘油酯和月桂基磺基乙酸钠。
-
-
-
-